Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: A 15-year regional surveillance study

The Lancet Global Health

Volumn 4, Issue 3, 2016, Pages e185-e194

  Hammitt, Laura L ^a,b   Crane, Rosie J ^a,c   Karani, Angela ^a   Mutuku, Alex ^a   Morpeth, Susan C ^a,c,d   Burbidge, Polly ^e   Goldblatt, David ^e   Kamau, Tatu ^f   Sharif, Shahnaaz ^f   Mturi, Neema ^a   Scott, J Anthony G ^a,c,d  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f Kenya Ministry of Health   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; HAEMOPHILUS VACCINE; VACCINE;

ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; BACTERIAL MENINGITIS; CHILD; CLINICAL EFFECTIVENESS; CROSS-SECTIONAL STUDY; DISEASE SURVEILLANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS MENINGITIS; HUMAN; IMMUNITY; INCIDENCE; INFLUENZA B; INFLUENZA VACCINATION; KENYA; NASOPHARYNX AIRWAY; PRESCHOOL CHILD; PREVALENCE; PRIORITY JOURNAL; SCHOOL CHILD; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; IMMUNIZATION; IMMUNOLOGY; INFANT; MALE; MICROBIOLOGY; NASOPHARYNX; PREVENTIVE HEALTH SERVICE; PROCEDURES;

CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; KENYA; MALE; NASOPHARYNX; PREVALENCE; VACCINES, CONJUGATE;

EID: 84959117770     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(15)00316-2     Document Type: Article

References (39)

1. Watt JP, Chen S, Santosham M Haemophilus influenzae type b conjugate vaccine: review of observational data on long term vaccine impact to inform recommendations for vaccine schedules 2012, World Health Organization, Geneva.
2. Peltola H Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000, 13:302-317.
3. Cowgill KD, Ndiritu M, Nyiro J, et al. Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya. JAMA 2006, 296:671-678.
4. WHO vaccine-preventable diseases: monitoring system. 2014 global summary WHO, (accessed Feb 8, 2015). http://apps.who.int/immunization_monitoring/globalsummary/schedules.
5. Johnson NG, Ruggeberg JU, Balfour GF, et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis 2006, 12:937-941.
6. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME Antibody to Haemophilus influenzae type b after routine and catch-up vaccination. Lancet 2003, 361:1523-1524.
7. Rodriguez RS, Mascarenas C, Conde-Glez CJ, et al. Serological protection induced by Haemophilus influenzae type B conjugate vaccine in Mexican children: is a booster dose of the vaccine needed?. Clin Vaccine Immunol 2010, 17:1639-1641.
8. Howie SR, Oluwalana C, Secka O, et al. The effectiveness of conjugate Haemophilus influenzae type B vaccine in The Gambia 14 years after introduction. Clin Infect Dis 2013, 57:1527-1534.
9. Haemophilus influenzae type b (Hib) vaccination position paper-July 2013. Wkly Epidemiol Rec 2013, 88:413-426. WHO.
10. Scott JA, Bauni E, Moisi JC, et al. Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). Int J Epidemiol 2012, 41:650-657.
11. Kenya AIDS indicator survey 2012: final report 2014, National AIDS and STI Control Program (NASCOP), KenyaKenya, National AIDS and STI Control Program, Nairobi, Kenya.
12. Maaroufi Y, De Bruyne JM, Heymans C, Crokaert F Real-time PCR for determining capsular serotypes of Haemophilus influenzae. J Clin Microbiol 2007, 45:2305-2308.
13. Hammitt LL, Akech DO, Morpeth SC, et al. Population effect of 10-valent pneumococcal conjugate vaccine on nasopharyngeal carriage of Streptococcus pneumoniae and non-typeable Haemophilus influenzae in Kilifi, Kenya: findings from cross-sectional carriage studies. Lancet Glob Health 2014, 2:e397-e405.
14. Bejon P, Mwacharo J, Kai O, et al. A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials 2006, 1:e29.
15. Mwangi TW, Ross A, Snow RW, Marsh K Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis 2005, 191:1932-1939.
16. Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. J Immunol Methods 1990, 135:121-128.
17. Abdullahi O, Nyiro J, Lewa P, Slack M, Scott JA The descriptive epidemiology of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in children and adults in Kilifi district, Kenya. Pediatr Infect Dis J 2008, 27:59-64.
18. Kayhty H, Peltola H, Karanko V, Makela PH The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983, 147:1100.
19. Moisi JC, Kabuka J, Mitingi D, Levine OS, Scott JA Spatial and socio-demographic predictors of time-to-immunization in a rural area in Kenya: Is equity attainable?. Vaccine 2010, 28:5725-5730.
20. Ndiritu M, Cowgill KD, Ismail A, et al. Immunization coverage and risk factors for failure to immunize within the Expanded Programme on Immunization in Kenya after introduction of new Haemophilus influenzae type b and hepatitis b virus antigens. BMC Public Health 2006, 6:132.
21. Garcia S, Lagos R, Munoz A, et al. Impact of vaccination against Haemophilus influenzae type b with and without a booster dose on meningitis in four South American countries. Vaccine 2012, 30:486-492.
22. von Gottberg A, Cohen C, Whitelaw A, et al. Invasive disease due to Haemophilus influenzae serotype b ten years after routine vaccination, South Africa, 2003-2009. Vaccine 2012, 30:565-571.
23. Mackenzie GA, Ikumapayi UN, Scott S, et al. Increased disease due to Haemophilus influenzae type b: population-based surveillance in eastern Gambia, 2008-2013. Pediatr Infect Dis J 2015, 34:e107-e112.
24. McVernon J, Trotter CL, Slack MP, Ramsay ME Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ 2004, 329:655-658.
25. Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet 2005, 366:144-150.
26. Michaels RH, Poziviak CS, Stonebraker FE, Norden CW Factors affecting pharyngeal Haemophilus influenzae type b colonization rates in children. J Clin Micro 1976, 4:413-417.
27. Odutola A, Antonio M, Owolabi O, et al. Comparison of the prevalence of common bacterial pathogens in the oropharynx and nasopharynx of Gambian infants. PLoS One 2013, 8:e75558.
28. Campagne G, Garba A, Schuchat A, et al. Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. Am J Trop Med Hyg 1998, 59:837-842.
29. Metz JA, Hanieh S, Pradhan R, et al. Evaluation of Haemophilus influenzae type b vaccine for routine immunization in Nepali infants. Pediatr Infect Dis J 2012, 31:e66-e72.
30. Sow SO, Tapia MD, Diallo S, et al. Haemophilus influenzae type B conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protection. Am J Trop Med Hyg 2009, 80:1033-1038.
31. Hutter J, Pasetti MF, Sanogo D, Tapia MD, Sow SO, Levine MM Naturally acquired and conjugate vaccine-induced antibody to Haemophilus influenzae type b (Hib) polysaccharide in Malian children: serological assessment of the Hib immunization program in Mali. Am J Trop Med Hyg 2012, 86:1026-1031.
32. Kelly DF, Moxon ER, Yu LM, Pollard AJ Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom. Clin Vaccine Immunol 2009, 16:246-252.
33. Bradshaw MW, Schneerson R, Parke JC, Robbins JB Bacterial antigens cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b. Lancet 1971, 1:1095-1096.
34. Neter E Antigenic relationship between H. influenzae type b and pneumococcus type VI. Proc Soc Exp Biol Med 1943, 52:289-292.
35. Schneerson R, Bradshaw M, Whisnant JK, Myerowitz RL, Parke JC, Robbins JB An Escherichia coli antigen cross-reactive with the capsular polysaccharide of Haemophilus influenzae type b: occurrence among known serotypes, and immunochemical and biologic properties of E coli antisera toward H influenzae type b. J Immunol 1972, 108:1551-1562.
36. Zepp HD, Hodes HL Antigenic relation of type b H. influenzae to type 29 and type 6 pneumococci. Proc Soc Exp Biol Med 1943, 52:315-317.
37. Adegbola RA, DeAntonio R, Hill PC, et al. Carriage of Streptococcus pneumoniae and other respiratory bacterial pathogens in low and lower-middle income countries: a systematic review and meta-analysis. PLoS One 2014, 9:e103293.
38. Morpeth SC. Understanding the dynamics and spread of pneumococcal infection from healthy carriage to pneumonia and invasive disease, in Kilifi, Kenya. PhD thesis, Open University, 2014.
39. van den Bergh MR, Spijkerman J, Swinnen KM, et al. Effects of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D-conjugate vaccine on nasopharyngeal bacterial colonization in young children: a randomized controlled trial. Clin Infect Dis 2013, 56:e30-e39.